PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
66.4 ^USD	+3.39%		-0.49%	+58.43%

15/05	Transcript : PROCEPT BioRobotics Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
06/05	Piper Sandler Adjusts Price Target on PROCEPT BioRobotics to $75 From $67, Maintains Overweight Rating	MT

PROCEPT BioRobotics : 2024 Bank of America Heathcare Conf

May 16, 2024 at 12:04 am IST

2024 Bank of America Heathcare Conf

May 15, 2024 at 12:20 PM EDT

Click here to go the event

Attachments

Original Link
Permalink

Disclaimer

Procept Biorobotics Corporation published this content on 15 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 18:33:08 UTC.

Latest news about PROCEPT BioRobotics Corporation

Transcript : PROCEPT BioRobotics Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM	15/05
Piper Sandler Adjusts Price Target on PROCEPT BioRobotics to $75 From $67, Maintains Overweight Rating	06/05	MT
PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia	06/05	CI
Procept BioRobotics Insider Sold Shares Worth $1,200,000, According to a Recent SEC Filing	06/05	MT
Procept BioRobotics Insider Sold Shares Worth $1,916,428, According to a Recent SEC Filing	06/05	MT
Transcript : PROCEPT BioRobotics Corporation - Analyst/Investor Day	03/05
Truist Raises PROCEPT BioRobotics' PT to $72 From $63 After 'Solid' Q1 Beat, Keeps Buy Rating	02/05	MT
Procept BioRobotics Shares Rise After Q1 Loss Narrows, Revenue Increases; 2024 Revenue Guidance Revised	01/05	MT
Transcript : PROCEPT BioRobotics Corporation, Q1 2024 Earnings Call, May 01, 2024	01/05
PROCEPT BioRobotics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Reports Q1 Revenue $44.5M, vs. Street Est of $41.7M	01/05	MT
Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024	01/05	CI
PROCEPT BioRobotics Corporation Announces Board and Committee Changes	20/04	CI
Procept Biorobotics Insider Sold Shares Worth $263,243, According to a Recent SEC Filing	21/03	MT
Procept Biorobotics Insider Sold Shares Worth $428,384, According to a Recent SEC Filing	08/03	MT
Procept Biorobotics Insider Sold Shares Worth $970,643, According to a Recent SEC Filing	07/03	MT
PROCEPT BioRobotics Q4 Net Loss Narrows as Revenue Increases	28/02	MT
Transcript : PROCEPT BioRobotics Corporation, Q4 2023 Earnings Call, Feb 27, 2024	28/02
Earnings Flash (PRCT) PROCEPT BIOROBOTICS Posts Q4 Revenue $43.6M, vs. Street Est of $41.9M	28/02	MT
PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024	28/02	CI
PROCEPT BioRobotics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Procept Biorobotics Insider Sold Shares Worth $1,121,062, According to a Recent SEC Filing	14/02	MT
Procept Biorobotics Insider Sold Shares Worth $1,481,579, According to a Recent SEC Filing	10/02	MT
Procept Biorobotics Insider Sold Shares Worth $999,367, According to a Recent SEC Filing	10/02	MT
Procept Biorobotics Insider Sold Shares Worth $719,475, According to a Recent SEC Filing	12/01	MT

Chart PROCEPT BioRobotics Corporation

Duration

Period

More charts

Company Profile

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Sector

Medical Equipment, Supplies & Distribution

Calendar

04/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for PROCEPT BioRobotics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.4 USD

Average target price

73.83 USD

Spread / Average Target

+11.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PROCEPT BIOROBOTICS CORPORATION	+58.43%	330.25Cr
ABBOTT LABORATORIES	-7.16%	18TCr
BECTON, DICKINSON AND COMPANY	-4.86%	6.55TCr
DEXCOM, INC.	-4.28%	4.71TCr
CENCORA, INC.	+10.32%	4.34TCr
HOYA CORPORATION	+8.14%	4.18TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	2.95TCr
TERUMO CORPORATION	+15.53%	2.48TCr
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	2.4TCr
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	2.35TCr

Other Medical Equipment, Supplies & Distribution